Robotics stock with massive upside

(Full access for Members only)

Robotics stock with massive upside

16 November 2023

High-tech industries are fast-moving and difficult to predict.

That's why I like to check what insiders are doing.

The company featured in today's research report has long had one of the world's best long-term investors among its shareholders. Said investor has excellent access to management and other investors, and even though he is not legally an "insider", he has to count as one for practical purposes.

Recently, he decided it was time to invest a triple-digit million amount, hovering up stock around its current price level.

After increasing his stake, he told a financial publication why he did so – he has followed the company and its technology for years, and believes it's about to make a massive leap forward.

What could this leap consist of?

This is what this research report is looking at in great detail.

It spells out:

  • How this company has not one, but multiple potential catalysts for 2024.
  • Why it's 50-100% too cheap right now, even based on its existing business.
  • Why its stock could increase by a multiple over the coming years.

I, too, have been following this stock for years. Its share price is currently down-and-out, but the underlying fundamentals are looking good – possibly, better than ever!

There is a real "perception gap" for this stock, and I believe the narrative will change soon.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.